Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Rigel Pharmaceuticals Inc (RIGL) since 2005 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Rigel Pharmaceuticals Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1034842.
Total stock buying since 2005: $7,157,880.
Total stock sales since 2005: $11,478,278.
Total stock option exercises since 2005: $3,375,809.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 19,830 | $424,175 | 90,000 | $1,925,999 |
| 2024 | 0 | $0 | 80,041 | $90,909 | 0 | $0 |
| 2023 | 0 | $0 | 36,506 | $62,429 | 0 | $0 |
| 2022 | 1,000,000 | $688,000 | 0 | $0 | 0 | $0 |
| 2019 | 50,000 | $106,500 | 0 | $0 | 0 | $0 |
| 2018 | 314,000 | $907,898 | 189,500 | $659,045 | 169,500 | $397,635 |
| 2017 | 0 | $0 | 110,000 | $415,455 | 100,000 | $214,000 |
| 2016 | 0 | $0 | 5,303 | $21,212 | 0 | $0 |
| 2015 | 0 | $0 | 51,666 | $190,725 | 41,666 | $89,165 |
| 2014 | 0 | $0 | 41,000 | $127,660 | 0 | $0 |
| 2013 | 32,700 | $113,403 | 484,622 | $1,280,371 | 0 | $0 |
| 2012 | 0 | $0 | 114,153 | $1,190,542 | 100,002 | $649,010 |
| 2011 | 650,000 | $5,200,000 | 0 | $0 | 0 | $0 |
| 2010 | 0 | $0 | 38,555 | $291,090 | 0 | $0 |
| 2009 | 0 | $0 | 0 | $0 | 53,334 | $96,001 |
| 2007 | 12,000 | $117,970 | 0 | $0 | 2,222 | $3,999 |
| 2005 | 2,000 | $24,109 | 327,026 | $6,724,665 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-02 | 0 | $0 | 19,830 | $424,175 | 0 | $0 |
| 2025-01 | 0 | $0 | 0 | $0 | 90,000 | $1,925,999 |
| 2024-02 | 0 | $0 | 80,041 | $90,909 | 0 | $0 |
| 2023-02 | 0 | $0 | 36,506 | $62,429 | 0 | $0 |
| 2022-06 | 1,000,000 | $688,000 | 0 | $0 | 0 | $0 |
| 2019-05 | 50,000 | $106,500 | 0 | $0 | 0 | $0 |
| 2018-10 | 0 | $0 | 10,000 | $31,200 | 0 | $0 |
| 2018-09 | 100,000 | $325,550 | 169,500 | $593,365 | 169,500 | $397,635 |
| 2018-08 | 214,000 | $582,348 | 0 | $0 | 0 | $0 |
| 2018-07 | 0 | $0 | 5,000 | $13,930 | 0 | $0 |
| 2018-04 | 0 | $0 | 5,000 | $20,550 | 0 | $0 |
| 2017-11 | 0 | $0 | 100,000 | $390,000 | 100,000 | $214,000 |
| 2017-07 | 0 | $0 | 5,000 | $13,425 | 0 | $0 |
| 2017-01 | 0 | $0 | 5,000 | $12,030 | 0 | $0 |
| 2016-08 | 0 | $0 | 5,303 | $21,212 | 0 | $0 |
| 2015-06 | 0 | $0 | 41,666 | $153,205 | 41,666 | $89,165 |
| 2015-04 | 0 | $0 | 10,000 | $37,520 | 0 | $0 |
| 2014-12 | 0 | $0 | 1,000 | $2,220 | 0 | $0 |
| 2014-09 | 0 | $0 | 20,000 | $51,200 | 0 | $0 |
| 2014-02 | 0 | $0 | 20,000 | $74,240 | 0 | $0 |
| 2013-11 | 0 | $0 | 484,622 | $1,280,371 | 0 | $0 |
| 2013-06 | 32,700 | $113,403 | 0 | $0 | 0 | $0 |
| 2012-09 | 0 | $0 | 102,453 | $1,085,289 | 98,302 | $637,977 |
| 2012-08 | 0 | $0 | 1,700 | $18,043 | 1,700 | $11,033 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-02-05 | Santos David A (EVP, Chief Commercial Officer) | Sale | 1,796 | 21.93 | 39,379 |
| 2025-02-05 | Furey Raymond J. (EVP, GC, CCO & Corp Sec) | Sale | 1,339 | 21.93 | 29,358 |
| 2025-02-05 | Schorno Dean L (EVP & Chief Financial Officer) | Sale | 1,734 | 21.93 | 38,019 |
| 2025-02-05 | Rodriguez Raul R (CEO, President) | Sale | 4,400 | 21.93 | 96,474 |
| 2025-02-04 | Santos David A (EVP, Chief Commercial Officer) | Sale | 2,125 | 20.92 | 44,457 |
| 2025-02-04 | Furey Raymond J. (EVP, GC, CCO & Corp Sec) | Sale | 1,448 | 20.92 | 30,293 |
| 2025-02-04 | Schorno Dean L (EVP & Chief Financial Officer) | Sale | 2,036 | 20.92 | 42,595 |
| 2025-02-04 | Rodriguez Raul R (CEO, President) | Sale | 4,952 | 20.92 | 103,600 |
| 2025-01-24 | Rodriguez Raul R (CEO, President) | Option Ex | 90,000 | 21.40 | 1,925,999 |
| 2024-02-05 | Santos David A (EVP, Chief Commercial Officer) | Sale | 8,918 | 1.14 | 10,166 |
| 2024-02-05 | Schorno Dean L (EVP & Chief Financial Officer) | Sale | 7,027 | 1.14 | 8,010 |
| 2024-02-05 | Rodriguez Raul R (CEO, President) | Sale | 30,545 | 1.14 | 34,821 |
| 2024-02-02 | Santos David A (EVP, Chief Commercial Officer) | Sale | 5,601 | 1.13 | 6,329 |
| 2024-02-02 | Schorno Dean L (EVP & Chief Financial Officer) | Sale | 5,601 | 1.13 | 6,329 |
| 2024-02-02 | Rodriguez Raul R (CEO, President) | Sale | 22,349 | 1.13 | 25,254 |
| 2023-02-06 | Rodriguez Raul R (CEO, President) | Sale | 20,340 | 1.75 | 35,595 |
| 2023-02-02 | Santos David A (EVP, Chief Commercial Officer) | Sale | 5,388 | 1.66 | 8,944 |
| 2023-02-02 | Dummer Wolfgang (EVP & CMO) | Sale | 5,389 | 1.66 | 8,945 |
| 2023-02-02 | Schorno Dean L (EVP & Chief Financial Officer) | Sale | 5,389 | 1.66 | 8,945 |
| 2022-06-09 | Rodriguez Raul R (CEO, President) | Buy | 1,000,000 | .69 | 688,000 |
| 2019-05-22 | Schorno Dean L (EVP &Chief Financial Officer) | Buy | 50,000 | 2.13 | 106,500 |
| 2018-10-12 | Cabatuan Nelson (Principal Accounting Officer) | Sale | 10,000 | 3.12 | 31,200 |
| 2018-09-17 | Duliege Anne-marie (EVP & Chief Medical Officer) | Sale | 153,000 | 3.50 | 535,500 |
| 2018-09-17 | Duliege Anne-marie (EVP & Chief Medical Officer) | Option Ex | 153,000 | 2.33 | 355,725 |
| 2018-09-11 | Mayer Eldon C. Iii (EVP & Chief Commercial Officer) | Buy | 50,000 | 3.23 | 161,350 |
| 2018-09-10 | Mayer Eldon C. Iii (EVP & Chief Commercial Officer) | Buy | 50,000 | 3.28 | 164,200 |
| 2018-09-04 | Duliege Anne-marie (EVP & Chief Medical Officer) | Sale | 16,500 | 3.51 | 57,865 |
| 2018-09-04 | Duliege Anne-marie (EVP & Chief Medical Officer) | Option Ex | 16,500 | 2.54 | 41,910 |
| 2018-08-23 | Mayer Eldon C. Iii (EVP & Chief Commercial Officer) | Buy | 100,000 | 2.82 | 282,300 |
| 2018-08-17 | Rodriguez Raul R (CEO, President) | Buy | 114,000 | 2.63 | 300,048 |
| 2018-07-02 | Duliege Anne-marie (EVP & Chief Medical Officer) | Sale | 5,000 | 2.79 | 13,930 |
| 2018-04-20 | Duliege Anne-marie (EVP & Chief Medical Officer) | Sale | 5,000 | 4.11 | 20,550 |
| 2017-11-03 | Maynard Ryan D (EVP & CFO) | Sale | 100,000 | 3.90 | 390,000 |
| 2017-11-03 | Maynard Ryan D (EVP & CFO) | Option Ex | 100,000 | 2.14 | 214,000 |
| 2017-07-05 | Duliege Anne-marie (Chief Medical Officer) | Sale | 5,000 | 2.69 | 13,425 |
| 2017-01-03 | Duliege Anne-marie (Chief Medical Officer) | Sale | 5,000 | 2.41 | 12,030 |
| 2016-08-30 | Payan Donald G (EVP, Pres. Discovery&Research) | Sale | 5,303 | 4.00 | 21,212 |
| 2015-06-10 | Payan Donald G (EVP, Pres. Discovery&Research) | Sale | 41,666 | 3.68 | 153,205 |
| 2015-06-10 | Payan Donald G (EVP, Pres. Discovery&Research) | Option Ex | 41,666 | 2.14 | 89,165 |
| 2015-04-01 | Payan Donald G (EVP, Pres. Discovery&Research) | Sale | 10,000 | 3.75 | 37,520 |
| 2014-12-18 | Vance Dolly (EVP Corp. Affairs, G.C., Sect.) | Sale | 1,000 | 2.22 | 2,220 |
| 2014-09-03 | Payan Donald G (EVP, Pres. Discovery&Research) | Sale | 20,000 | 2.56 | 51,200 |
| 2014-02-24 | Payan Donald G (EVP, Pres. Discovery&Research) | Sale | 20,000 | 3.71 | 74,240 |
| 2013-11-19 | Bvf Investments Llc (Other) | Sale | 484,622 | 2.64 | 1,280,371 |
| 2013-06-07 | Lampert Mark N (10% Owner) | Buy | 32,700 | 3.47 | 113,403 |
| 2012-09-13 | Vance Dolly (EVP Corp. Affairs, G.C., Sect.) | Sale | 4,151 | 10.43 | 43,282 |
| 2012-09-10 | Maynard Ryan D (EVP & CFO) | Sale | 17,586 | 10.52 | 184,934 |
| 2012-09-10 | Maynard Ryan D (EVP & CFO) | Option Ex | 17,586 | 6.49 | 114,133 |
| 2012-09-07 | Maynard Ryan D (EVP & CFO) | Sale | 57,414 | 10.61 | 608,511 |
| 2012-09-07 | Maynard Ryan D (EVP & CFO) | Option Ex | 57,414 | 6.49 | 372,615 |
| 2012-08-07 | Maynard Ryan D (EVP & CFO) | Sale | 1,700 | 10.61 | 18,043 |
| 2012-08-07 | Maynard Ryan D (EVP & CFO) | Option Ex | 1,700 | 6.49 | 11,033 |
| 2012-06-19 | Payan Donald G (EVP, Pres. Discovery&Research) | Sale | 10,000 | 8.72 | 87,210 |
| 2011-05-26 | Deerfield International Ltd | Buy | 650,000 | 8.00 | 5,200,000 |
| 2010-11-03 | Deerfield Special Situations Fund International Ltd | Sale | 23,133 | 7.55 | 174,654 |
| 2009-01-02 | Payan Donald G (EVP, Pres. Discovery&Research) | Option Ex | 3,334 | 1.80 | 6,001 |
| 2009-01-02 | Gower James M (CEO & Board Chairman) | Option Ex | 50,000 | 1.80 | 90,000 |
| 2007-08-09 | Goodwin Bradford S | Buy | 10,000 | 9.86 | 98,620 |
| 2007-06-26 | Moos Walter H | Option Ex | 2,222 | 1.80 | 3,999 |
| 2007-05-29 | Grossbard Elliott B (Sr. VP Medical Development) | Buy | 2,000 | 9.68 | 19,350 |
| 2005-12-07 | Cooper Robin D G (Sr. V.P. Pharmaceuti) | Buy | 1,000 | 8.12 | 8,119 |
| 2005-07-27 | Deleage Jean (Director) | Sale | 171,997 | 20.40 | 3,509,082 |
| 2005-07-25 | Deleage Jean (Director) | Sale | 6,400 | 20.37 | 130,348 |
| 2005-07-21 | Deleage Jean (Director) | Sale | 586 | 20.75 | 12,159 |
| 2005-07-20 | Deleage Jean (Director) | Sale | 148,043 | 20.76 | 3,073,076 |
| 2005-03-30 | Vance Dolly (Gen.Counsel) | Buy | 1,000 | 15.99 | 15,990 |
Insider trading activities including stock purchases, stock sales, and option exercises of RIGL listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Rigel Pharmaceuticals Inc (symbol RIGL, CIK number 1034842) see the Securities and Exchange Commission (SEC) website.